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Background
• Lipid lowering has been shown to be beneficial for primary and secondary 
prevention of coronary artery disease in patients with dyslipidemias
• Statin mechanism of action: competitively inhibits HMG CoA reductase (rate limiting step in 
cholesterol biosynthesis)
• Administration of statin therapy guided primarily by risk of CVD
• Atherosclerotic cardiovascular disease (ASCVD) risk calculation for use only in adult 
patients without known ASCVD and LDL 70-189 mg/dL
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. doi: 10.1161/​01.cir.0000437741.48606.98.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. doi: 10.1161/​01.cir.0000437738.63853.7a.
Robinson G, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. 
European Heart Journal, 2015. 36, 2110–2118 doi:10.1093/eurheartj/ehv182.
Robinson G, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. 
European Heart Journal, 2015. 36, 2110–2118 doi:10.1093/eurheartj/ehv182.
Study Design 
• Empiric observational study 
• Retrospective chart review of 2,994 patients for information including ASCVD risk 
determination and active statin prescription
• Inclusion Criteria: Adult patients visiting the K15 Academic Internal Medicine Clinic of Henry Ford 
Hospital from January 2017- December 2017
• Primary objective: to assess appropriateness of statin therapy based on ASCVD risk calculation 
and ACC/AHA guidelines.
• Secondary objective: to assess correlation between patient demographic and appropriateness 
of statin therapy according to guidelines. 
• Clinical implication: determine proper application of ASCVD guidelines and better improve 
patient outcomes in the outpatient setting
Results
1,548 patients were prescribed inappropriate statin dose
- 1,245 patients taking high-intensity statin did not qualify for one based on ASCVD risk 
p-value < 0.001
p-value < 0.001
Female patients 81.9% more likely to be on appropriate statin dose vs male patients OR 1-1.819, 95% CI, 1.559-2.124
Black patients were 32.2% less likely to be on appropriate statin dose vs Caucasian patients OR 1-0.678, 95% CI, 0.5320-0.864 
Patients on appropriate statin dose have a higher family income on average 
- Every 10,000-unit increase in income, increases the odds of an appropriate statin dose by 2.4% 
p-value = 0.020
OR 1-1.024, 95% CI, 0.990-1.060
For every 1-unit increase in age, the odds of an appropriate statin dose decrease by 4.8% OR 1-0.952, 95% CI, 0.04-0.056
Limitations
• Varying demographics specific to location of Henry Ford Hospital
• Socioeconomic status
• Lack of access to healthcare and/or medical insight
• Internal validity: 
• Misclassified subgroup: appropriate statin dose misassigned to high
• Stroke/TIA not considered in risk status determination
• Limitations inherent to observational study design
• May represent older prescribing practices
• Not fully reflective of current trends
Looking ahead…
• Treatment according to AHA/ACC guidelines based on ASCVD risk calculation has well documented effect on 
morbidity and mortality   
• Appropriate administration of statins by dose and intensity is a necessary intervention aimed at improving 
patient outcomes
• HF pilot program promoting pharmacist-driven initiation and dosing of statins
• Improving adherence
• Improving administration
• Improving clinical outcomes
• Assessing clinical outcomes in sites with policies in place for initiation and administration of appropriate 
dose/intensity statin 
Thank you!
Questions?
